

84. (new) The compound of claim 59 wherein the compound of Formula (I) is:



85. (new) The compound of claim 59 wherein the compound of Formula (I) is:



86. (new) The compound of claim 59 wherein the compounds are effective antagonists of an integrin receptor.

87. (new) The compound of claim 86 wherein the compound is a selective antagonist of an α4 integrin receptor.

88. (new) The compound of claim 87 wherein the α4 integrin receptor is selected from the group consisting of the α4β1 and α4β7 integrin receptor.

89. (new) The compound of claim 87 wherein the compound is an antagonist of at least two α4 integrin receptors.

90. (new) The compound of claim 89 wherein the two α4 integrin receptors are selected from the group consisting of the α4β1 and α4β7 integrin receptor.

91. (new) The compound of claim 59 wherein R_7 is selected from the group consisting tolyl, phenyl and thienyl.

92. (new) A compound having Formula (II):



Formula (II)

wherein

Y is selected from the group consisting of -C(O)- and $-SO_2-$;

R_1 is selected from the group consisting of R_7 and R_8;

R_2, R_3, R_4 and R_5 are independently hydrogen or C_{1-8}alkyl; wherein C_{1-8}alkyl is optionally substituted with one to three substituents independently selected from R_9;

R_6 is optionally present and is one to three substituents independently selected from the group consisting of halogen, C_{1-8}alkoxy, R_{10}, R_{12}, $-N(R_{11})C(O)-R_{10}$, $-N(R_{11})C(O)-R_{12}$, $-N(R_{11})SO_2-R_{10}$, $-N(R_{11})SO_2-R_{12}$, $-N(R_{11})C(O)-N(R_{11},R_{10})$, $-N(R_{11})C(O)-N(R_{11},R_{12})$, $-N(R_{11})C(O)-N(R_{12},R_{17})$, $-C(O)-N(R_{11},R_{10-})$, $-C(O)-N(R_{11},R_{12})$, $-C(O)-N(R_{12},R_{17})$, $-OC(O)-N(R_{11},R_{10})$,

comprising reacting a compound of Formula (IV)



Formula (IV)

wherein

R_{16} is selected from the group consisting of halogen, mixed anhydride and hydroxy;

with a compound of Formula (V)



Formula (V);

in the presence of appropriate coupling agents, bases and solvents to form the compound of Formula (II).

94. (new) The process of claim 93 wherein R_{15} is selected from the group consisting of hydroxy, iodine, bromine, and NO_2.

95. (new) A pharmaceutical composition comprising a compound of claim 59 and a pharmaceutically acceptable carrier.

96. (new) A pharmaceutical composition made by mixing a compound of claim 59 and a pharmaceutically acceptable carrier.

97. (new) A method for the treatment of an integrin mediated disorder ameliorated by inhibition of an α4 integrin receptor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 59.

EX. A

98. (new) The method of claim 97 wherein the α4 integrin receptor is selected from the group consisting of the α4β1 and α4β7 integrin receptor.

99. (new) The method of claim 97 wherein the compound inhibiting the α4 integrin receptor is selected from the group consisting of a selective antagonist of the α4β1 integrin receptor, a selective antagonist of the α4β7 integrin receptor and an antagonist of the α4β1 and α4β7 integrin receptors.

100. (new) The method of claim 97 wherein the integrin mediated disorder is selected from the group consisting of inflammatory disorders, autoimmune disorders and cell-proliferative disorders.

A method of treating integrin mediated disorder selected from the group consisting of

101. (new) ~~The method of claim 97 wherein the integrin mediated disorder is selected from the group consisting of inflammation disorders, autoimmunity disorders,~~ asthma, bronchoconstriction, restenosis, atherosclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, irritable bowel disease, irritable bowel syndrome, transplant rejection and multiple sclerosis, comprising administering to a subject in need thereof, a therapeutically effective amount of a Compound of claim 59.

102. (new) The method of claim 97 wherein the integrin mediated disorder is selected from the group consisting of asthma, bronchoconstriction, restenosis, atherosclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, irritable bowel disease, irritable bowel syndrome, transplant rejection and multiple sclerosis.

103. (new) The method of claim ~~97~~ 101 wherein the integrin mediated disorder is selected from the group consisting of asthma, bronchoconstriction, restenosis, atherosclerosis, irritable bowel syndrome and multiple sclerosis.

104. (new) The method of claim 97 wherein the therapeutically effective amount of the compound is from about 0.01 mg/kg/day to about 300 mg/kg/day.

105. (new) The method of claim 97 further comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of the compound and a pharmaceutically acceptable excipient.

106. (new) The method of claim 105 wherein the therapeutically effective amount of the pharmaceutical composition of the compound and a pharmaceutically acceptable excipient is from about 0.01 mg/kg/day to about 300 mg/kg/day.

107. (new) The method of claim 97 wherein the integrin mediated disorder is a cell-proliferation disorders.